MBX Biosciences, Inc.
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 38.75% | 36.08% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 5.70% | 7.81% | |||
| Operating Income | -5.70% | -7.81% | |||
| Income Before Tax | -6.60% | -2.05% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -6.60% | -2.05% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -6.60% | -2.05% | |||
| EBIT | -5.70% | -7.81% | |||
| EBITDA | -5.70% | -7.79% | |||
| EPS Basic | -2.68% | 22.21% | |||
| Normalized Basic EPS | 9.59% | 9.49% | |||
| EPS Diluted | -2.68% | 22.21% | |||
| Normalized Diluted EPS | 9.59% | 9.49% | |||
| Average Basic Shares Outstanding | 3.81% | 31.19% | |||
| Average Diluted Shares Outstanding | 3.81% | 31.19% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||